2015
Immune biomarkers associated with clinical benefit from atezolizumab (MPDL3280a; anti-PD-L1) in advanced urothelial bladder cancer (UBC)
Powles T, Nickles D, Van Allen E, Chappey C, Zou W, Kowanetz M, Kadel E, Denker M, Boyd Z, Vogelzang N, Kim J, Bellmunt J, Loriot Y, Drake C, O'Hear C, Fasso M, Hegde P, Mariathasan S. Immune biomarkers associated with clinical benefit from atezolizumab (MPDL3280a; anti-PD-L1) in advanced urothelial bladder cancer (UBC). Journal For ImmunoTherapy Of Cancer 2015, 3: p83. PMCID: PMC4645499, DOI: 10.1186/2051-1426-3-s2-p83.Peer-Reviewed Original ResearchA phase Ia study of MPDL3280A (anti-PDL1): Updated response and survival data in urothelial bladder cancer (UBC).
Petrylak D, Powles T, Bellmunt J, Braiteh F, Loriot Y, Cruz Zambrano C, Burris H, Kim J, Teng S, Bruey J, Hegde P, Abidoye O, Vogelzang N. A phase Ia study of MPDL3280A (anti-PDL1): Updated response and survival data in urothelial bladder cancer (UBC). Journal Of Clinical Oncology 2015, 33: 4501-4501. DOI: 10.1200/jco.2015.33.15_suppl.4501.Peer-Reviewed Original ResearchEmerging immunotherapies for bladder cancer
Kim JW, Tomita Y, Trepel J, Apolo AB. Emerging immunotherapies for bladder cancer. Current Opinion In Oncology 2015, 27: 191-200. PMID: 25811346, PMCID: PMC7709951, DOI: 10.1097/cco.0000000000000177.Peer-Reviewed Original ResearchConceptsUrothelial carcinomaImmune escapeImmune systemTumor antigen presentationAdvanced urothelial carcinomaBenefit of immunotherapyImmune escape mechanismsFraction of patientsHigh mutational burdenImmune-mediated cytotoxicityMultiple tumor typesDurable responsesImmune checkpointsBladder cancerClinical trialsT cellsCombinatorial regimensTumor antigensMutational burdenImmunotherapyClinical developmentCarcinomaTumor typesTumor cellsEscape mechanisms
2014
Examining the management of muscle-invasive bladder cancer by medical oncologists in the United States11Funding source: The US Office of Management and Budget (0925-0046).
Apolo AB, Kim JW, Bochner BH, Steinberg SM, Bajorin DF, Kelly K, Agarwal PK, Koppie TM, Kaag MG, Quinn DI, Vogelzang NJ, Sridhar SS. Examining the management of muscle-invasive bladder cancer by medical oncologists in the United States11Funding source: The US Office of Management and Budget (0925-0046). Urologic Oncology Seminars And Original Investigations 2014, 32: 637-644. PMID: 24840869, PMCID: PMC6771274, DOI: 10.1016/j.urolonc.2013.12.012.Peer-Reviewed Original ResearchConceptsMuscle-invasive bladder cancerTreatment of MIBCUpper tract urothelial carcinomaNeoadjuvant chemotherapyMedical oncologistsUrothelial carcinomaBladder cancerEastern Cooperative Oncology Group performance statusHigh grade upper tract urothelial carcinomaBladder Cancer Advocacy NetworkUse of NACDose-dense methotrexateGemcitabine/carboplatinGemcitabine/cisplatinGlomerular filtration rateAdjuvant chemotherapyPerioperative chemotherapyChemotherapy regimensLymphovascular invasionPerformance statusT2 lesionsStandardization of practiceMost referralsFiltration rateChemotherapy management